With 35.42 million shares changed hands, the volume of the stock remained heavier than its average volume of 22.5 million shares. The 52-week range on RXRX shows that it touched its highest point at $14.16 and its lowest point at $5.60 during that stretch. It currently has a 1-year price target of $8.60. Beta for the stock currently stands at 0.82.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RXRX was down-trending over the past week, with a drop of -19.07%, but this was up by 4.89% over a month. Three-month performance surged to 25.17% while six-month performance fell -1.31%. The stock lost -51.61% in the past year, while it has gained 11.09% so far this year. A look at the trailing 12-month EPS for RXRX yields -1.53 with Next year EPS estimates of -1.24. For the next quarter, that number is -0.41. This implies an EPS growth rate of 18.24% for this year and 10.62% for next year.
Float and Shares Shorts:
At present, 390.76 million RXRX shares are outstanding with a float of 297.00 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RXRX since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.45054 being high and -$1.62696 being low. For RXRX, this leads to a yearly average estimate of -$1.53875.
